You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 19, 2024

Litigation Details for In Re: Opana ER Antitrust Litigation (N.D. Ill. 2014)


✉ Email this page to a colleague

« Back to Dashboard


In Re: Opana ER Antitrust Litigation (N.D. Ill. 2014)

Docket ⤷  Sign Up Date Filed 2014-12-12
Court District Court, N.D. Illinois Date Terminated 2022-07-01
Cause 28:1331 Federal Question Assigned To Matthew F. Kennelly
Jury Demand Defendant Referred To
Parties MEIJER, INC.
Patents 6,022,539; 6,228,398; 6,294,195; 6,495,155; 7,229,636; 7,276,250; 7,404,489; 7,718,640; 7,811,560; 7,851,482; 7,879,349; 8,003,353; 8,075,872; 8,114,383; 8,192,722; 8,309,060; 8,309,122; 8,329,216; 8,338,395; 8,808,737; 8,871,779; 8,940,714; 9,119,876; 9,295,657; 9,375,478; 9,415,007; 9,687,526; 9,744,209; 9,744,239; 9,750,785; 9,937,223; RE39,941
Attorneys Joseph R. Saveri
Firms Keker, Van Nest & Peters LLP
Link to Docket External link to docket
Small Molecule Drugs cited in In Re: Opana ER Antitrust Litigation
The small molecule drugs covered by the patents cited in this case are ⤷  Sign Up , ⤷  Sign Up , ⤷  Sign Up , ⤷  Sign Up , ⤷  Sign Up , ⤷  Sign Up , ⤷  Sign Up , ⤷  Sign Up , ⤷  Sign Up , ⤷  Sign Up , and ⤷  Sign Up .
Biologic Drugs cited in In Re: Opana ER Antitrust Litigation

The biologic drugs covered by the patents cited in this case are ⤷  Sign Up , ⤷  Sign Up , and ⤷  Sign Up .

Details for In Re: Opana ER Antitrust Litigation (N.D. Ill. 2014)

Date Filed Document No. Description Snippet Link To Document
2015-05-04 102 for what ultimately issued as U.S. Patent No. 7,276,250 patent entitled “Sustained release formulations…the Orange Book patents because: (1) no patents exist on the brand drug; (2) the patents have expired;…artificial act” of patent infringement, permitting the patent owner to file a patent infringement suit…ER. This patent is expected to provide patent protection until November 2023. The new patent will be listed…limitations on the types of patents that can be listed. Only drug substance patents (active ingredient), drug External link to document
2016-02-10 151 patent”), No. 5,662,933 (the “‘933 patent”), and No. 7,276,250 …purchased the rights to four patents — U.S. Patent No. 5,128,143 (the “143 patent”), No. 5,958,456 (the …of any unexpired patents listed in the Orange Book; or (IV) that any unexpired patents listed in the Orange…artificial act” of patent infringement, permitting the brand company to file a patent infringement suit… ‘143 patent in the Orange Book as covering Opana ER, and later added the ‘456 and ‘933 patents. External link to document
2016-02-25 162 “‘456 patent”), No. 5,662,933 (the “‘933 patent”), and No. 7,276,250 (the “‘250 patent”) (collectively… rights to four patents — U.S. Patent No. 5,128,143 (the “‘143 patent”), No. …expiration of the Penwest Patents, and Endo sued each for patent infringement. RAC ¶¶ 84-109…enforceability of the ‘933 and ‘456 patents, as well as the ‘250 patent, which Endo had not even accused…agreement to settle ongoing patent infringement Case: 1:14-cv-10150 Document External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.